NCT06017219 is a NA clinical trial of spermidine in Healthy Subjects, sponsored by Chrysea Labs Lda.

Who is sponsoring NCT06017219?

NCT06017219 is sponsored by Chrysea Labs Lda.

What drugs are being tested in NCT06017219?

Interventions in NCT06017219: spermidine.

What condition does NCT06017219 study?

NCT06017219 studies Healthy Subjects.

Is NCT06017219 still recruiting?

NCT06017219 is currently active, enrolled. Last updated 30 August 2024.

Last reviewed 2024-08-30 · How we verify

NCT06017219

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioavailability of Spermidine in Healthy Males

Active, enrolled NA Last updated 30 August 2024

What this trial tests

NA trial testing spermidine in Healthy Subjects in 6 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 May 2023

Primary endpoint
15 October 2023

14 December 2024

Quick facts

Lead sponsor	Chrysea Labs Lda
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Enrollment	6
Start date	5 May 2023
Primary completion	15 October 2023
Estimated completion	14 December 2024
Sites	1 location across Ireland

Drugs / interventions tested

spermidine — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Chrysea Labs Lda

Who can join

Adults 18 to 70, male only, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate in healthy males the safety of two doses of spermidine as assessed by occurrence of any Adverse Events/Serious adverse events.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mitophagy in the pathogenesis and management of disease.
Wang Q, Sun Y, Li TY, Auwerx J. · · 2026 · cited 1× · PMID 41486294 · DOI 10.1038/s41422-025-01203-7
Insights into the therapeutic strategies for aging and aging-associated diseases.
Dong R, Wu Q, Kan J, Fu C, et al · · 2026 · PMID 42225652 · DOI 10.1038/s41392-026-02662-z

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06017219 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chrysea Labs Lda
Last refreshed: 30 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06017219.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing